TABLE 1

Patient Characteristics

Treatment	TNM stage at diagnosis	Site of metastatic lesions	Sex	Age at therapy (y)	DTC histology	Number of previous ¹³¹I therapies*
1	Tx N0 M0	Lymph node neck	F	82	Papillary	5 (35.1)
2	T4 N0 M0	Lung	F	70	Follicular	3 (18.4)
3^†	T4 N0 M0	Local recurrence	M	78	Follicular	7 (48.1)
4	Tx N1 M0	Lung	M	67	Follicular	4 (27.7)
5	T4 N0 M1	Lung/mediastinum	M	83	Follicular	2 (11.1)
6^†	T4 N0 M0	Local recurrence	M	79	Follicular	8 (55.5)
7	T3 N0 M1	Lung, liver, and bone	F	70	Follicular	2 (14.8)
8^‡	T4 N0 M1	Lung	F	72	Follicular	1 (3.7)
9	Tx N0 M0	Skull	M	71	Follicular	3 (14.8)
10^†	T4 N0 M0	Local recurrence	M	79	Follicular	9 (62.9)
11	T2 N0 M0	Lymph node neck	F	64	Papillary	2 (11.1)
12	Tx N0 M0	Lymph node neck	F	87	Papillary	1 (3.7)
13^‡	T4 N0 M1	Lung	F	73	Follicular	2 (11.1)
14	T4 N0 M0	Lung	F	73	Follicular	1 (3.7)
15	T2 N0 M1	Lung	M	70	Papillary	2 (14.8)
16	T4 N1 M1	Lymph node neck	F	41	Papillary	2 (12.9)
17	T4 N0 M0	Lung	M	78	Follicular	2 (12.9)

↵* Includes thyroid remnant ablation. Cumulative activity, in gigabecquerels, is in parentheses.
↵^† Patient received 3 rhTSH-aided treatments.
↵^‡ Patient received 2 rhTSH-aided treatments.